CJC-1295
Modified Growth Hormone Releasing Factor GRF(1-29) Tetrasubstituted
CJC-1295 is a tetrasubstituted 29-amino-acid synthetic peptide analog of growth hormone-releasing hormone (GHRH). It is designed with substitutions at positions 2, 8, 15, and 27 to impart resistance against dipeptidyl peptidase-4 (DPP-4) enzymatic degradation.
Indexed for laboratory in vitro receptor binding assays and cellular synthesis research. Commercial materials are procured as non-clinical reagents under verified laboratory standards.
Chemical Structure & Metrics
Structured Chemical & Preclinical Profile
1. Chemical Identity & Sequence Architecture
CJC-1295 (Modified Growth Hormone Releasing Factor GRF(1-29) Tetrasubstituted) is an analytically characterized peptide with empirical formula C152H252N44O42 (MW 3367.97 g/mol). CAS Registry: 863288-34-0.
2. Primary Preclinical Signaling Axis
Investigated in preclinical assays for cellular signaling: Selective binding to pituitary somatotroph GHRH receptors, stimulating adenylate cyclase and cAMP pathways.
3. Physical Formats & Delivery Matrices
Synthesized predominantly as high-purity lyophilized powder cakes, with secondary pre-metered pen cartridges and solution atomizers cataloged across vendors.
4. Reconstitution & Analytical Handling
Recommended reconstitution with Bacteriostatic Water USP (0.9% Benzyl Alcohol). Lyophilized cake stored at -20°C dry vacuum. Solution stable at 2°C to 8°C refrigerated (stable 21 days).
Signaling Pathways & Laboratory Handling Protocols
Documented Receptor Pathways & In Vitro Signaling
Selective binding to pituitary somatotroph GHRH receptors, stimulating adenylate cyclase and cAMP pathways.
Promotion of physiologic pulsatile endogenous growth hormone secretion while preserving negative feedback loops.
Sustained stimulation of hepatic insulin-like growth factor 1 (IGF-1) transcription.
Preservation of pituitary responsiveness without downregulating prolactin or cortisol receptor selectivity.
Investigated in kinetic trials both with Drug Affinity Complex (DAC) and without DAC. Evaluated in human clinical kinetic trials for somatotroph secretagogue profiles.
Handling Parameters
Peptide Dilution & Reconstitution Calculator
Compute stock concentrations, micro-pipetting draw volumes, and U-100 syringe units with zero procedural guesswork.
Slowly introduce bacteriostatic diluent against the internal glass vial wall. Swirl gently in a circular horizontal rotation. Never shake or vortex vigorously to prevent mechanical shearing of delicate peptide bonds. Store reconstituted stock at 2°C–8°C.
Partner & Vendor Catalogues for CJC-1295
Independent partner directory providing research-grade lyophilized vials, cartridges, atomizers, and reconstitution solvents.
Category hub featuring research-grade lyophilized vials, pens, and blends.
Full catalogue category hub with multiple mg vial sizes and blends.
Dedicated category hub listing research vials and cartridges.
UK-stocked research reagent catalogue hub featuring batch-verified peptide lots.
Global catalogue hub including international dispatch batches.
Academic Bibliography & Preclinical Studies for CJC-1295
Primary academic indexing sourced from PubMed and peer-reviewed biotechnology journals documenting molecular mechanisms and in vitro cellular response.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I by CJC-1295 in healthy subjects
Substituted growth hormone-releasing hormone analogs with extended in vivo half-lives
GHRH and its synthetic analogs: Neuroendocrine kinetics and therapeutic investigations
Frequently Asked Chemical & Analytical Questions
Authoritative scientific clarifications regarding CJC-1295 classification, molecular pathways, and laboratory protocols.
CJC-1295 (Modified Growth Hormone Releasing Factor GRF(1-29) Tetrasubstituted) is an analytically characterized peptide compound with empirical molecular formula C152H252N44O42 and molecular weight 3367.97 g/mol. It is indexed under CAS Registry Number 863288-34-0 and categorized in research literature under Growth Hormone Secretagogues & GHRH.